Abstract:Abstract Background The variation of drug responses and target does among individuals is mostly determined by genes. With the development of pharmacogenetics and pharmacogenomics, the differences in drug response between different races seem to be mainly caused by the genetic diversity of pharmacodynamics and pharmacokinetics genes. Very important pharmacogenetic (VIP) variants mean that genes or variants play important and vital roles in drug response, which have been listed in pharmacogenomics databases, such as Pharmacogenomics Knowledge Base (PharmGKB). The information of Chinese ethnic minorities such as the Wa ethnic group is scarce. This study aimed to uncover the significantly different loci in the Wa population in Yunnan Province of China from the perspective of pharmacogenomics, to provide a theoretical basis for the future medication guidance, and to ultimately achieve the best treatment in the future. Results In this study, we recruited 200 unrelated healthy Wa adults from the Yunnan province of China, selected 52 VIP variants from the PharmGKB for genotyping. We also compared the genotype frequency and allele distribution of VIP variants between Wa population and the other 26 populations from the 1000 Genomes Project ( http://www.1000Genomes.org/ ). Next, χ 2 test was used to determine the significant points between these populations. The study results showed that compared with the other 26 population groups, five variants rs776746 ( CYP3A5 ), rs4291 ( ACE ), rs3093105 (CYP4F2 ), rs1051298 ( SLC19A1 ), and rs1065852 ( CYP2D6 ) had higher frequencies in the Wa population. The genotype frequencies rs4291-TA, rs3093105-CA, rs1051298-AG and rs1065852-GA were higher than those of the other populations, and the allele distributions of rs4291-T and rs3093105-C were significantly different. Additionally, the difference between the Wa ethnic group and East Asian populations, such as CDX, CHB, and CHS, was the smallest. Conclusions Our research results show that there is a significant difference in the distribution of VIP variants between the Wa ethnic group and the other 26 populations. The study results will have an effect on supplementing the pharmacogenomics information for the Wa population and providing a theoretical basis for individualised medication for the Wa population.

The landscape of very important pharmacogenes variants and potential clinical relevance in the Chinese Jingpo population: a comparative study with worldwide populations

Identification and Functional Assessment of EightCYP3A4Allelic Variants39–46Detected in the Chinese Han Population

Very important pharmacogenetic variants landscape and potential clinical relevance in the Zhuang population from Yunnan province

Very Important Pharmacogenes Polymorphism Landscape and Potential Clinical Relevance in the Chinese Mongolian.

Genetic Polymorphisms in Very Important Pharmacogenomic Variants in the Zhuang Ethnic Group of Southwestern China

Genetic Polymorphisms of Pharmacogenomic VIP Variants in the Hui Population from Ningxia Province of China.

Analysis of Very Important Pharmacogene Variants in the Tibetan Population from China

Genetic Polymorphisms of Pharmacogenomic VIP Variants in the Yi Population from China

Population Genetic Difference of Pharmacogenomic VIP Variants in the Tibetan Population

Genetic Polymorphisms of Very Important Pharmacogene Variants in the Blang Population from Yunnan Province in China

Genetic polymorphisms of pharmacogenomic VIP variants in the Mongol of Northwestern China

Genetic Analysis of Pharmacogenomic VIP Variants in the Blang Population from Yunnan Province of China

Genetic Variation of Pharmacogenomic VIP Variants in Zhuang Nationality of Southern China

Genetic Polymorphisms of Very Important Pharmacogene Variants in the Chinese Lisu Population

Genetic analysis of pharmacogenomic VIP variants in the Wa population from Yunnan Province of China

Genetic Variation of Pharmacogenomic VIP Variants in the Chinese Li Population: an Updated Research.

Evaluation of Clinical Impact of Pharmacogenomics Knowledge Involved in CPIC Guidelines on Chinese Pediatric Patients

Genetic Polymorphisms of Pharmacogenomic Vip Variants in Li Nationality of Southern China

Genetic Polymorphisms Study of Pharmacogenomic VIP Variants in Han Ethnic of China's Shaanxi Province.

Genetic Polymorphisms Analysis of Pharmacogenomic VIP Variants in Miao Ethnic Group of Southwest China

Genetic Polymorphisms in Very Important Pharmacogenomic (VIP) Variants in the Tibetan Population